AXL and non-small cell lung carcinoma: Selective blockade of Axl by bemcentinib in combination with pembrolizumab in NSCLC and melanoma is currently being explored in two Phase 2 trials BGBC008 (NCT03184571) and BGBIL006 (NCT02872259).